Dipeptidyl peptidase‐4 inhibitor might exacerbate Graves’ disease: A multicenter observational case–control study

Dipeptidyl peptidase‐4 inhibitor might exacerbate Graves’ disease: A multicenter observational case–control study

Abstract Dipeptidyl peptidase‐4 (DPP‐4), namely CD26, is expressed on the surface of immune cells, suggesting that inhibition of DPP‐4 might affect the immune system. The current multicenter observational case–control study was carried out to investigate the effects of DPP‐4 inhibitor (DPP‐4i) admin...

Full description

Bibliographic Details
Main Authors: Tomonori Sekizaki, Hiraku Kameda, Hiroshi Nomoto, Kyu Yong Cho, Akinobu Nakamura, Kiyohiko Takahashi, Arina Miyoshi, Norio Wada, Jun Takeuchi, So Nagai, Hideaki Miyoshi, Tatsuya Atsumi
Format: Article
Language:English
Published: Wiley 2021-11-01
Series:Journal of Diabetes Investigation
Subjects:
Dipeptidyl peptidase‐4
Graves' disease
Case‐control study
Online Access:https://doi.org/10.1111/jdi.13578

Internet

https://doi.org/10.1111/jdi.13578

Similar Items